just remember this stock was at $3 on January 31 before CoVid fix was needed, we were not involved in finding a fix, when things settle down it should go back to that level and then rise or fall based on Trial results without including CoVid. The question is if this proves up in the near future with expanded CoVid Trial then anyones guess where it goes.
Ann: 83% Survival in COVID-19 ARDS Patients with Remestemcel-L, page-263
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |